Package Leaflet: Information for the Patient
Solibu400 mg solution for infusion EFG
Ibuprofen
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Ibuprofen belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). These medicines provide relief by changing the body's response to pain and high temperature.
This medicine is indicated for the short-term symptomatic treatment of moderate pain and fever, when intravenous administration is clinically justified and other routes of administration are not possible.
Do not use Solibu
if you are in the last three months of pregnancy (see below).
Warnings and precautions
Consult your doctor or nurse before starting to use this medicine:
You should discuss your treatment with your doctor or nurse before using Solibu if:
Signs of allergic reaction to this medicine, such as respiratory problems, swelling of the face and neck (angioedema), and chest pain, have been reported with ibuprofen. Stop using Solibu immediately and contact your doctor or medical emergency service immediately if you notice any of these signs.
Infections
Solibu may hide the signs of an infection, such as fever and pain. Consequently, Solibu may delay the appropriate treatment of the infection, which may increase the risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If you take this medicine while having an infection and the symptoms of the infection persist or worsen, consult a doctor without delay.
Skin reactions
Serious skin reactions have been reported with Solibu treatment. Stop taking Solibu and go to the doctor immediately if you present any skin rash, lesions on the mucous membranes, blisters or other signs of allergy, as these may be the first signs of a very serious skin reaction. See section 4.
Children and adolescents
The safety of Solibu in the pediatric population has not been established, Solibu should not be used by children or adolescents (under 18 years of age).
Using Solibu with other medicines
Tell your doctor if you are using, have recently used or might use any other medicines.
Solibu may affect or be affected by other medicines. For example:
Other medicines may also affect or be affected by treatment with Solibu. Therefore, you should always consult your doctor or nurse before using Solibu with other medicines.
Taking ibuprofen may alter the following laboratory tests:
Tell your doctor if you are going to have a clinical analysis and are using or have recently used ibuprofen.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Ibuprofen is contraindicated during the third trimester of pregnancy, as it may harm the fetus or cause problems during delivery. It may cause kidney and heart problems in your fetus. It may affect you and your baby's tendency to bleed and delay or prolong labor more than expected. You should not take ibuprofen during the first six months of pregnancy unless clearly necessary and as indicated by your doctor. If you need treatment during this period or while trying to become pregnant, you should take the minimum dose for the shortest possible time. From the 20th week of pregnancy, ibuprofen may cause kidney problems in your fetus if taken for more than a few days, which may cause low levels of amniotic fluid surrounding the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the baby's heart. If you need treatment for more than a few days, your doctor may recommend additional checks.
Talk to your doctor or nurse before taking this product if you are in the first six months of pregnancy or are breastfeeding.
This medicine passes into breast milk, but may be used during breastfeeding at the recommended dose and for the shortest possible time.
Ibuprofen belongs to a group of medicines that may affect fertility in women. This effect is reversible if the medicine is stopped. It is unlikely to affect your chances of becoming pregnant if used occasionally. However, consult your doctor before starting to take this medicine if you have problems becoming pregnant.
Driving and using machines
Solibu may have a minor influence on the ability to drive and use machines. Some isolated cases may experience dizziness and fatigue, so driving ability may be affected.
Solibu contains sodium
This medicine contains 13 mmol (303 mg) of sodium per 100 ml of solution, which should be taken into account in patients with a controlled sodium diet.
For the treatment of moderate pain and for the treatment of fever. Administer 400 mg of ibuprofen (100 ml of solution) intravenously every 6 hours as needed (provided the disease does not progress and the patient continues to tolerate the treatment) for a maximum of 3 days.
The recommended daily dose is 1200 mg of ibuprofen.
The lowest effective dose should be used for the shortest time necessary to relieve symptoms. If you have an infection, consult a doctor without delay if the symptoms (such as fever and pain) persist or worsen (see section 2).
The ibuprofen solution should be administered as an intravenous infusion over 30 minutes.
If you use more Solibu than you should
Consult a doctor immediately. If you have taken more Solibu than you should, or if a child has accidentally ingested the medicine, consult a doctor immediately or go to the nearest hospital to find out about the risk and ask for advice on the measures to be taken.
Symptoms of overdose may include nausea, stomach pain, vomiting (which may contain blood clots), gastrointestinal bleeding (see also section 4), diarrhea, headache, ringing in the ears, confusion and involuntary eye movement. Agitation, drowsiness, disorientation or coma may also occur. Occasionally, patients develop convulsions. At high doses, symptoms of drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness and dizziness, blood in the urine, low potassium levels in the blood, chills and breathing problems have been reported. Additionally, the prothrombin time/INR may be prolonged, probably due to interference with the actions of circulating coagulation factors. Acute kidney failure and liver damage may occur. Exacerbation of asthma in asthmatics is also possible. Additionally, hypotension and decreased respiration may occur.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects can be minimized by using the lowest dose for the shortest time necessary to relieve symptoms. If you get any side effects, or are unsure if you have any side effects, stop taking this medicine and talk to your doctor as soon as possible. People over 65 years of age who use this product are at greater risk of developing problems related to side effects.
Stop using this medicine and seek medical help immediately if you develop:
Talk to your doctor if you get any of the following side effects, if they get worse, or if you notice any other side effects not listed here.
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Very rare: may affect up to 1 in 10,000 people
Frequency not known:
Reporting of side effects
If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Before administration, the product should be visually inspected. Do not use this medication if you observe any particles or if the solution has changed color.
For single use. Once the product is opened, it should be used immediately. The remaining solution should not be used and should be discarded.
Composition of Solibu
The active ingredient is ibuprofen.
Each ml of solution contains 4 mg of ibuprofen.
Each 100 ml bag contains 400 mg of ibuprofen.
The other components are trometamol, sodium chloride, hydrochloric acid, sodium hydroxide, and water for injectable preparations.
Appearance of the Product and Package Contents
Solibu is a clear and colorless solution packaged in 100 ml polyolefin bags with an aluminum foil wrapper.
Solibu 400 mg solution for infusion is available in:
Cases containing 20 and 50 bags of 100 ml.
Marketing Authorization Holder
Altan Pharmaceuticals, S.A.
C/ Cólquide 6, Portal 2, 1ª Planta, oficina F. Edificio Prisma
28230 Las Rozas (Madrid) Spain
Manufacturer
Altan Pharmaceuticals, S.A.
Polígono Industrial de Bernedo s/n
01118 Bernedo (Álava) Spain
Date of the Last Revision of this Prospectus: December 2024